Introduction to Synthetic Lethality in Precision Oncology

Precision medicine continues to evolve by identifying unique vulnerabilities in tumor cells. When chromosomal deletions occur, they often remove tumor suppressor genes alongside adjacent passenger genes. This collateral loss creates a state of synthetic lethality. Specifically, the loss of FOCAD, a gene located near CDKN2A and MTAP on chromosome 9p21, induces a critical dependency on the HBS1L/PELO ribosome-rescue complex. To exploit this, researchers developed TNG961, a first-in-class HBS1L molecular glue degrader that offers a potent therapeutic strategy for these genetically defined cancers.

Mechanisms of the HBS1L/PELO Ribosome-Rescue Complex

The HBS1L/PELO complex is vital for maintaining translational homeostasis by rescuing stalled ribosomes. In healthy cells, the SKI complex, which includes the FOCAD protein, helps manage aberrant mRNA. However, when FOCAD is deleted, the SKI complex destabilizes, leading to an accumulation of stalled ribosomes. Consequently, these cancer cells become hyper-dependent on HBS1L to survive. By using an HBS1L molecular glue degrader, clinicians can selectively induce proteasomal degradation of this essential rescue factor, leading to translational arrest and cell death.

Therapeutic Potential of the HBS1L Molecular Glue Degrader TNG961

TNG961 emerged from an intensive medicinal chemistry campaign guided by cryo-EM structures. It promotes a ternary complex between HBS1L and the E3 ligase cereblon, facilitating rapid ubiquitination. Furthermore, preclinical studies demonstrate that oral administration of TNG961 leads to significant tumor regression in various xenograft models. Notably, this HBS1L molecular glue degrader remains effective even in models that have become refractory to PRMT5 inhibitors. This finding is particularly relevant because FOCAD is co-deleted in approximately one-third of MTAP-deleted cancers, providing a secondary line of attack for difficult-to-treat malignancies.

Clinical Implications and Future Directions

The development of TNG961 signifies a major step forward in targeting mRNA quality control pathways. Because TNG961 is orally bioavailable and highly selective, it minimizes off-target degradation of canonical neosubstrates like IKZF1. Moreover, the high prevalence of 9p21 deletions in solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer, suggests a broad potential patient population. Researchers are now moving toward clinical evaluation to confirm the efficacy and safety of this first-in-class therapeutic in human subjects.

Frequently Asked Questions

What is the mechanism of action for TNG961?

TNG961 acts as a molecular glue that brings HBS1L into proximity with the cereblon E3 ligase complex. This leads to the selective ubiquitination and subsequent proteasomal degradation of HBS1L, disrupting ribosome rescue in FOCAD-deleted cells.

Why is FOCAD deletion a therapeutic target?

FOCAD loss disrupts the SKI complex, making cells unable to process aberrant mRNA efficiently. This creates a synthetic lethal dependency on the HBS1L/PELO complex for ribosome recycling, which TNG961 exploits to kill tumor cells while sparing healthy tissue.

Is TNG961 effective against drug-resistant cancers?

Yes, preclinical data show that TNG961 induces tumor regression in models that are refractory to PRMT5 inhibitors, suggesting it could be a vital treatment option for patients who have progressed on existing precision therapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Nicholson HE et al. TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers. Cancer Discov. 2026 Apr 19. doi: 10.1158/2159-8290.CD-26-0040. PMID: 42001523.


2. Lazarides K, et al. HBS1L/PELO ribosome-rescue complex dependency in FOCAD-deleted cancers. AACR Annual Meeting; 2025.


3. Tango Therapeutics. Pipeline - HBS1L TNG961 Molecular Glue Degrader for FOCAD-deleted Solid Tumors. 2026.